These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

339 related items for PubMed ID: 1716788

  • 1. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase.
    St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, Kellam P, Kemp SD, Larder BA.
    Science; 1991 Sep 27; 253(5027):1557-9. PubMed ID: 1716788
    [Abstract] [Full Text] [Related]

  • 2. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine.
    Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA.
    J Virol; 1992 Dec 27; 66(12):7128-35. PubMed ID: 1279198
    [Abstract] [Full Text] [Related]

  • 3. pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo.
    Eron JJ, Chow YK, Caliendo AM, Videler J, Devore KM, Cooley TP, Liebman HA, Kaplan JC, Hirsch MS, D'Aquila RT.
    Antimicrob Agents Chemother; 1993 Jul 27; 37(7):1480-7. PubMed ID: 7689822
    [Abstract] [Full Text] [Related]

  • 4. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.
    Larder BA, Kohli A, Bloor S, Kemp SD, Harrigan PR, Schooley RT, Lange JM, Pennington KN, St Clair MH.
    J Virol; 1996 Sep 27; 70(9):5922-9. PubMed ID: 8709213
    [Abstract] [Full Text] [Related]

  • 5. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study.
    Shirasaka T, Yarchoan R, O'Brien MC, Husson RN, Anderson BD, Kojima E, Shimada T, Broder S, Mitsuya H.
    Proc Natl Acad Sci U S A; 1993 Jan 15; 90(2):562-6. PubMed ID: 8380641
    [Abstract] [Full Text] [Related]

  • 6. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
    Chow YK, Hirsch MS, Merrill DP, Bechtel LJ, Eron JJ, Kaplan JC, D'Aquila RT.
    Nature; 1993 Feb 18; 361(6413):650-4. PubMed ID: 7679778
    [Abstract] [Full Text] [Related]

  • 7. Response of Ethiopian human immunodeficiency virus type 1 isolates to antiviral compounds.
    Wondimu Z, Sönnerborg A, Ayehunie S, Britton S, Strannegård O.
    Antiviral Res; 1992 Oct 01; 19(4):353-9. PubMed ID: 1281393
    [Abstract] [Full Text] [Related]

  • 8. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro.
    Johnson VA, Merrill DP, Videler JA, Chou TC, Byington RE, Eron JJ, D'Aquila RT, Hirsch MS.
    J Infect Dis; 1991 Oct 01; 164(4):646-55. PubMed ID: 1716649
    [Abstract] [Full Text] [Related]

  • 9. Genotypic evolution of HIV-1 isolates from patients after a switch of therapy from zidovudine to didanosine.
    Masquelier B, Pellegrin I, Ruffault A, Ragnaud JM, Morlat P, Michelet C, Doignon F, Biteau N, Fleury HJ.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Apr 01; 8(4):330-4. PubMed ID: 7533640
    [Abstract] [Full Text] [Related]

  • 10. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA, Kellam P, Kemp SD.
    Nature; 1993 Sep 30; 365(6445):451-3. PubMed ID: 7692302
    [Abstract] [Full Text] [Related]

  • 11. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy.
    Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC.
    J Infect Dis; 1995 Dec 30; 172(6):1480-5. PubMed ID: 7594706
    [Abstract] [Full Text] [Related]

  • 12. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy.
    Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, Merigan TC.
    J Virol; 1996 Feb 30; 70(2):1086-90. PubMed ID: 8551567
    [Abstract] [Full Text] [Related]

  • 13. In vitro selection of variants of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine.
    Gao Q, Gu ZX, Parniak MA, Li XG, Wainberg MA.
    J Virol; 1992 Jan 30; 66(1):12-9. PubMed ID: 1727474
    [Abstract] [Full Text] [Related]

  • 14. Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI.
    Reichman RC, Tejani N, Lambert JL, Strussenberg J, Bonnez W, Blumberg B, Epstein L, Dolin R.
    Antiviral Res; 1993 Apr 30; 20(4):267-77. PubMed ID: 8097906
    [Abstract] [Full Text] [Related]

  • 15. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).
    Larder BA, Kemp SD.
    Science; 1989 Dec 01; 246(4934):1155-8. PubMed ID: 2479983
    [Abstract] [Full Text] [Related]

  • 16. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 17. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment.
    Di Stefano M, Sabri F, Leitner T, Svennerholm B, Hagberg L, Norkrans G, Chiodi F.
    J Clin Microbiol; 1995 Feb 15; 33(2):352-5. PubMed ID: 7536214
    [Abstract] [Full Text] [Related]

  • 18. Reverse transcriptase mutations in sequential HIV-1 isolates in a patient with AIDS.
    Gurusinghe AD, Land SA, Birch C, McGavin C, Hooker DJ, Tachedjian G, Doherty R, Deacon NJ.
    J Med Virol; 1995 Jul 15; 46(3):238-43. PubMed ID: 7561796
    [Abstract] [Full Text] [Related]

  • 19. Long-term persistence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of dideoxyinosine-treated patients removed from zidovudine therapy.
    Smith MS, Koerber KL, Pagano JS.
    J Infect Dis; 1994 Jan 15; 169(1):184-8. PubMed ID: 7506280
    [Abstract] [Full Text] [Related]

  • 20. [Investigation of AZT susceptibility of sequential HIV-1 isolates from patients treated with ddI after long-term therapy with AZT].
    Saito T, Kondo M, Ito A, Nagao T, Hayashi T, Watanabe S, Imai M.
    Kansenshogaku Zasshi; 1994 Jul 15; 68(7):819-23. PubMed ID: 8089546
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.